Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Normal Skin Clear all
Completed Not applicable Interventional

Hula, a Physical Activity Intervention for Female-Cancer Survivors

NCT02351479
View directory record Official record
Conditions
Physical Activity, Breast Cancer, Cervical Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Hula
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
21 Years and older · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer

NCT02689427
View directory record Official record
Conditions
Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Axillary Lymph Node Dissection, Enzalutamide, Laboratory Biomarker Analysis, Lymph Node Biopsy, Paclitaxel, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

NCT01074970
View directory record Official record
Conditions
Breast Cancer
Interventions
Cisplatin, Rucaparib
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
27
States / cities
Fullerton, California • Los Angeles, California • Santa Maria, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

NCT03137069
View directory record Official record
Conditions
Urticaria
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Not listed Phase 1Phase 2 Interventional

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

NCT00538005
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
bevacizumab, oxaliplatin, sorafenib tosylate
Biological · Drug
Lead sponsor
San Diego Pacific Oncology & Hematology Associates
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers

NCT01885962
View directory record Official record
Conditions
Spinal Cord Injury, Pressure Ulcers
Interventions
iSHIFTup
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Fishersville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

NCT01264770
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Fostamatinib and placebo injections, Adalimumab and placebo of fostamatinib, Placebo of fostamatinib, fostamatinib, and placebo injections
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers

NCT01769573
View directory record Official record
Conditions
Healthy Volunteers
Interventions
RG-HRV16, Placebo
Biological · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma

NCT03958383
View directory record Official record
Conditions
Melanoma
Interventions
hu14.18-IL2, Radiation Therapy, Nivolumab, Ipilimumab
Biological · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities

NCT01431105
View directory record Official record
Conditions
Kawasaki Disease
Interventions
Atorvastatin
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tegaderm vs. EyeGard for Eye Protection

NCT03549429
View directory record Official record
Conditions
Erythema
Interventions
Medical tapes: TegadermTM and EyeGard®
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

NCT01321502
View directory record Official record
Conditions
Herpes
Interventions
famciclovir
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed No phase listed Observational

Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing

NCT03341559
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Spatial Frequency Domain Imaging (SFDI)
Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

NCT03007979
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of Breast, Malignant Tumor of Breast
Interventions
Palbociclib, Letrozole, Fulvestrant, Optional research biopsy, Goserelin, Research blood draw, Circulating tumor cell blood draw, Tumor biopsy (optional)
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
St Louis, Missouri • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

NCT00004196
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
recombinant interferon alfa, lymphangiography, Observation
Biological · Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2014 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label Safety Study of A-101 Solution

NCT02667288
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 2 Interventional Results available

Study Adding Multikinase Inhibitor Sorafenib to Existing Endocrine Therapy in Patients With Advanced Breast Cancer

NCT00525161
View directory record Official record
Conditions
Breast Cancer
Interventions
sorafenib
Drug
Lead sponsor
Suleiman Massarweh
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Jul 22, 2026, 12:02 PM EDT
Completed Phase 1 Interventional

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

NCT02820961
View directory record Official record
Conditions
Breast Cancer, Estrogen Receptor Positive Breast Cancer
Interventions
entinostat, exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Denver, Colorado • Sarasota, Florida • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 22, 2026, 12:02 PM EDT
Recruiting Not applicable Interventional

GammaPod Dose Escalation Radiation for Early Stage Breast Cancer

NCT04234386
View directory record Official record
Conditions
Breast Cancer
Interventions
GammaPod Radiation
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
45 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
4
States / cities
Baltimore, Maryland • Bel Air, Maryland • Columbia, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 22, 2026, 12:02 PM EDT
Terminated Phase 3 Interventional Results available

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

NCT00516269
View directory record Official record
Conditions
Breast Cancer, Fatigue, Gastrointestinal Cancer
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Not listed No phase listed Observational

Cellular and Tissue Based Therapy Registry

NCT02322554
View directory record Official record
Conditions
Diabetic Foot Ulcers, Venous Stasis Ulcer, Pressure Ulcer, Chronic Non Healing Wound, Surgical Wound Dehiscence
Interventions
Cellular and tissue based products
Biological
Lead sponsor
U.S. Wound Registry
Other
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 22, 2026, 12:02 PM EDT
Suspended Phase 2 Interventional

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00278122
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
sargramostim, paclitaxel
Biological · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Jul 22, 2026, 12:02 PM EDT